Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Trial Profile

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms LINE-AD
  • Most Recent Events

    • 19 Jul 2021 Planned initiation date changed from 1 Jul 2021 to 1 Oct 2021.
    • 03 Jun 2021 Planned initiation date changed from 15 Mar 2021 to 1 Jul 2021.
    • 26 Jan 2021 Planned primary completion date changed from 1 Feb 2023 to 31 Mar 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top